Compare NOMD & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMD | PVLA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2015 | 2013 |
| Metric | NOMD | PVLA |
|---|---|---|
| Price | $11.45 | $156.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $12.50 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 1.9M | 159.3K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,810,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.45 | $104,350.18 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | N/A | ★ 65.28 |
| 52 Week Low | $8.99 | $53.30 |
| 52 Week High | $14.33 | $161.38 |
| Indicator | NOMD | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 55.98 |
| Support Level | $10.99 | $135.68 |
| Resistance Level | $12.33 | $160.07 |
| Average True Range (ATR) | 0.36 | 7.65 |
| MACD | -0.06 | 0.24 |
| Stochastic Oscillator | 6.25 | 87.11 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.